TABLE 1.
| Demographic data | Resultc (n = 22) |
|---|---|
| Male, n (%) | 14 (63%) |
| Age (yr) | 41 (36-53) |
| wt (kg) at admission | 76 (70-90) |
| Body max index (kg/m2) | 26 (23-29) |
| No. of patients on RRT | 11 (50%) |
| CVVHDF | 5 (45%) |
| CVVHD | 3 (27%) |
| EDD | 2 (18%) |
| SLED | 1 (9%) |
| No. of patients by indications for ECMO | |
| Pneumonia | 5 (23%) |
| Cardiogenic shock | 4 (18%) |
| Heart transplant | 3 (14%) |
| ARDS | 2 (9%) |
| Sickle cell crisis | 1 (5%) |
| Myocarditis | 1 (5%) |
| Valve replacement | 1 (5%) |
| Cardiomyopathy | 1 (5%) |
| Cardiac arrest | 1 (5%) |
| Lung transplant | 1 (5%) |
| TRALI | 1 (5%) |
| Illness severity score | |
| APACHE II (on admission to ICU) | 17 (14-26) |
| SOFA (on sampling day) | 10 (8-12) |
| Native CrCL on day of sampling (ml/min)d | 75 (60-82) |
| Albumin (g/liter) | 24 (23-31) |
| Bilirubin (μmol/liter) | 28 (16-51) |
| Total protein (g/liter) | 51 (49-57) |
| Urea (mmol/liter) | 10 (8-12) |
| No. of patients by daily vancomycin dosing regimen | |
| Below 10 mg/kg | 1 (5%)e |
| 10-15 mg/kg | 2 (9%) |
| 15.1-20 mg/kg | 6 (27%) |
| 20.1-25 mg/kg | 4 (18%) |
| 25.1-30 mg/kg | 5 (23%) |
| 30.1-35 mg/kg | 3 (14%) |
| Above 35 mg/kg | 1 (5%) |
| ECMO circuit data | Result |
| No. of veno-venous/no. of veno-arterial | 9/13 (41%/59%) |
| Type of ECMO pump, n (%) | |
| Jostra Rotaflow | 18 (82%) |
| CardioHelp | 2 (9%) |
| Levitronix Centrimag | 2 (9%) |
| Type of ECMO oxygenator, n (%) | |
| Maquet Quadrox | 16 (73%) |
| Medos Hilite | 4 (18%) |
| Medtronic Affinity | 2 (9%) |
| Flow rate (liters/min) | 4.1 (3.5-5.4) |
| Days on ECMO before sampling | 8 (3-10) |
a
Data for 22 patients.
b
RRT, renal replacement therapy; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous haemodiafiltration; SLED, sustained low efficiency dialysis; EDD, extended daily diafiltration; ARDS, acute respiratory distress syndrome; TRALI, transfusion-related acute lung injury; APACHE II, acute physiology and chronic health evaluation II score; SOFA, sequential organ failure assessment.
c
Data displayed in median (IQR, interquartile range) or n (%) as appropriate.
d
Estimated creatinine clearance only included those patients not on renal replacement therapy (n = 11).
e
Loading dose.